by Gemma Escarré,
AB-Biotics, a CataloniaBio & HealthTech member company, has closed a deal with the Japan-based Kaneka Corporation that will give them exclusive rights in Japan and the United States. In exchange, AB-Biotics will take a percentage of the business generated in these markets.
This makes Kaneka Corporation the Catalan biotechnology firm’s largest shareholder, acquiring 34% of shares. The AB-Biotics founding partners, Miquel Àngel Bonachera and Sergi Audivert, are the second shareholders, with a 20.22% joint stake. Bonachera and Audivert noted that the operation will allow them to “accelerate growth over the coming years, with a top-notch strategic partner.”
Kaneka Corporation, founded in 1949, is a leading chemical company in the sector.
Photo: Miquel Àngel Bonachera and Sergi Audivert, founding partners of AB-Biotics.